does glp 1 affect kidneys GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists GLP-1 Medications & Their Potential

Many participants lost more than 25% at higher doses

ROS and inflammation are main mediators of vascular senescence

Clinical studies have provided strong evidence about GLP-1 safety

Cardiovascular Outcomes: The SELECT Trial Revolution Breakthrough Cardiovascular Evidence The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial represents a paradigm shift in obesity treatment by demonstrating cardiovascular benefits independent of diabetes status

They also trigger the release of insulin from the pancreas and inhibit the secretion of glucagon, a hormone that raises blood sugar levels

But the directional pressure is consistent across the board: the eating behaviors that generated add-on revenue in the prior decade are in structural decline